Brought to you by 
J&J's Janssen gets rights to Evotec's depression drug candidates
14 Jan 2016
Executive Summary
Johnson & Johnson’s Janssen Pharmaceuticals Inc. has licensed exclusive global rights to a series of Evotec AG’s small-molecule therapeutics. The NR2B subtype selective NMDA-antagonist portfolio is focused on the treatment of depression.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J's Janssen gets rights to Evotec's depression drug candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice